Saturday 17 October 2026
Export RCUS’s income statement to Excel — free account
Arcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024. In the quarter to June 2026, revenue fell 74.4%, EPS was flat, free cash flow grew 10.5% and total debt rose 4.12%, each against the same quarter a year earlier.
22.12
0.70
−3.07%
Follow RCUS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.04 | 10.36 | 11.48 | 33.23 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(14.93) | (21.33) | (19.63) | (32.67) | |
P/B ratio |
3.32 | 4.06 | 5.17 | 8.38 | |
Price to Tangible BV |
3.32 | 4.06 | 5.17 | 8.38 | |
EV/Sales |
2.98 | 6.79 | 8.42 | 28.09 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.55) | (3.48) | (4.07) | (6.93) | |
EV/FCF |
(1.54) | (3.47) | (4.05) | (6.90) | |
Quick Ratio |
3.58 | 4.29 | 3.95 | 3.73 | |
Current Ratio |
3.65 | 4.36 | 4.04 | 3.82 | |
Net Debt/EBITDA |
5.13 | 7.74 | 5.35 | 6.26 | |
Debt/Assets |
10.06% | 8.69% | 10.03% | 10.93% | |
Debt/Equity |
0.22 | 0.16 | 0.19 | 0.22 | |
Asset Turnover |
0.22 | 0.22 | 0.22 | 0.12 | |
Operating CF/Net income |
0.72 | 1.13 | 1.08 | 1.31 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Interest Coverage |
(47.33) | (57.00) | (44.67) | (32.00) | |
Research and Development Expense of Revenue |
542.31% | 366.67% | 717.65% | 275.61% | |
Selling, General and Administrative Expense of Revenue |
103.85% | 78.79% | 170.59% | 58.54% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
53.85% | 45.45% | 111.76% | 36.59% | |
Graham Net Nets |
0.22 | 0.20 | 0.14 | 0.08 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(25.29%) | (13.85%) | (14.72%) | (12.65%) | |
Free Cash Flow Yield |
(32.04%) | (18.91%) | (18.09%) | (12.24%) | |
Revenue per Share |
0.24 | 0.31 | 0.14 | 0.33 | |
Operating CF per Share |
(0.91) | (1.12) | (1.10) | (0.94) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.91) | (1.13) | (1.10) | (0.94) | |
Cash per Share |
7.80 | 9.13 | 6.56 | 5.57 | |
Shareholders Equity per Share |
4.09 | 5.88 | 4.18 | 3.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.09 | 5.88 | 4.18 | 3.68 | |
Free Cash Flow |
(97.00) | (121.00) | (138.00) | (119.00) | |
Working Capital |
622.00 | 776.00 | 635.00 | 558.00 | |
Capital Expenditures |
0.00 | (1.00) | — | — | |
Net Current Asset Value |
319.00 | 499.00 | 371.00 | 296.00 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.03 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
13.50 | 15.50 | 9.00 | 25.50 | |
Average Payables |
27.50 | 30.00 | 30.50 | 31.50 | |
Average Assets |
1,113.00 | 1,144.50 | 1,076.50 | 999.50 | |
Average Common Equity |
500.50 | 558.00 | 527.50 | 506.50 |
Columns are period end dates